Helicobacter Pylori Diagnostics Market Size & Growth Forecast 2027–2036, By Segments (Type, End-user, Technology), Regional Demand Trends (North America, Asia Pacific, Europe), Key Country Insights (U.S., Japan, South Korea, Germany, France, Italy), and Competitive Landscape
Market Size and Growth Outlook
Helicobacter Pylori Diagnostics Market size was worth USD 784.4 million in 2026 and is expected to grow at a 5.58% CAGR between 2027 and 2036, crossing USD 1.35 billion by 2036. The industry revenue for 2027 is assessed at USD 821.24 million.
Get more details on this report
Request Free Sample ReportHelicobacter Pylori Diagnostics Market Intelligence Snapshot
Regional Market Dynamics
- North America holds 50.85% share due to strong diagnostic infrastructure, broad testing availability, and routine gastrointestinal evaluation across hospitals and specialty clinics.
- Asia Pacific growth at 6.78% CAGR is driven by improved diagnostic access, rising test uptake, and expansion of cost-effective detection methods across healthcare systems.
Segment Momentum
- Reagents held a 47.14% share in 2026 because they are consumed continuously in routine H. pylori testing workflows, creating steady demand across diagnostic laboratories and healthcare settings.
- Diagnostics Laboratories are growing fastest due to their ability to efficiently manage rising testing volumes through specialized, streamlined workflows that support dependable turnaround times and scalable operations.
Market Expansion Drivers
- Increasing incidence of gastric ulcers and stomach cancer driving early-stage H. pylori diagnosis demand.
- Rising adoption of non-invasive diagnostic technologies improving patient-friendly infection detection capabilities.
- Advancements in PCR and biosensor technologies enhancing diagnostic sensitivity and antimicrobial resistance detection.
Leading Market Participants
- Top companies in the helicobacter pylori diagnostics market include Thermo Fisher Scientific Inc. (United States), Biohit Oyj (Finland), Quest Diagnostics Incorporated (United States), Meridian Bioscience, Inc. (United States), Bio-Rad Laboratories, Inc. (United States), Alpha Laboratories Ltd (United Kingdom), F. Hoffmann-La Roche Ltd (Switzerland), Coris BioConcept (Belgium), Certest Biotec S.L. (Spain), Epitope Diagnostics, Inc. (United States).
Global Market Forecast Snapshot
Market Outlook
- 2026 Market Size: USD 784.4 million
- 2027 Estimated Market Size: USD 821.24 million.
- Projected Market Size: USD 1.35 billion by 2036
- Growth Forecast: 5.58% CAGR (2027-2036)
Regional and Segment Outlook
- Leading Regional Market: North America
- High-Growth Regional Hub: Asia Pacific
- Core Revenue Segment: Reagents (Type) | Hospitals (End-user) | Immunoassays (Technology)
- Emerging Opportunity Segment: Instruments (Type) | Diagnostics Laboratories (End-user) | Molecular Diagnostics (Technology)
Market Growth Drivers and Industry Trends
Increasing incidence of gastric ulcers and stomach cancer driving early-stage H. pylori diagnosis demand
The increasing incidence of gastric ulcers and stomach cancer is strengthening demand for timely infection detection, supporting growth of the helicobacter pylori diagnostics market. H. pylori infection is closely associated with chronic gastric inflammation and the development of peptic ulcer disease, while persistent infection can contribute to gastric cancer risk. Greater clinical attention to identifying the infection at an earlier stage is encouraging physicians to incorporate H. pylori testing into the evaluation of patients with gastrointestinal symptoms and relevant risk factors. Earlier diagnosis also enables treatment to be initiated before persistent infection contributes to more severe gastric complications, increasing the need for accessible and dependable diagnostic testing.
Rising adoption of non-invasive diagnostic technologies improving patient-friendly infection detection capabilities
Patient preference for convenient testing methods is supporting the helicobacter pylori diagnostics market growth as healthcare providers increasingly use non-invasive approaches for infection detection. Breath tests and stool-based assays can identify infection without requiring invasive tissue sampling, making them suitable for initial assessment and follow-up testing in appropriate clinical settings. These methods can improve patient acceptance by reducing discomfort and simplifying the diagnostic process, while also supporting broader testing outside highly specialized procedures. Their practical advantages are particularly relevant when repeated assessment is required to evaluate whether infection has been successfully cleared following treatment.
Advancements in PCR and biosensor technologies enhancing diagnostic sensitivity and antimicrobial resistance detection
Advances in molecular diagnostics are strengthening the ability to identify H. pylori with greater analytical precision and, in selected applications, assess characteristics associated with antimicrobial resistance. The helicobacter pylori diagnostics market will benefit from PCR-based technologies that can detect bacterial genetic material and identify resistance-related markers from clinical samples. Biosensor development is also supporting faster detection approaches by enabling the recognition of specific biological targets through compact diagnostic platforms. Such technologies can provide clinicians with more detailed information for treatment decisions, particularly where increasing antimicrobial resistance makes accurate pathogen characterization more important.
| Growth Driver | Impact on CAGR | Regulatory Influence | Geographic Relevance | Adoption Rate | Impact Timeline |
|---|---|---|---|---|---|
| Increasing incidence of gastric ulcers and stomach cancer driving early-stage H. pylori diagnosis demand | 1.80% | High | North America, Asia Pacific | High | Near Term |
| Rising adoption of non-invasive diagnostic technologies improving patient-friendly infection detection capabilities | 1.60% | Moderate | Europe, North America | High | Mid Term |
| Advancements in PCR and biosensor technologies enhancing diagnostic sensitivity and antimicrobial resistance detection | 1.40% | Moderate | Asia Pacific, Europe | Medium | Mid Term |
Unlock insights tailored to your business with our bespoke market research solutions.
Click to get your customized report now.
Regional Demand Dynamics
North America (Largest Region)
In the helicobacter pylori diagnostics market, North America held the largest share of 50.85% in 2026, reflecting strong diagnostic infrastructure, widespread access to advanced testing methods, and established clinical pathways for detecting gastrointestinal infections. The region’s healthcare systems emphasize timely diagnosis and evidence-based treatment, supporting demand for reliable noninvasive and laboratory-based testing. Continued awareness of H. pylori-associated gastrointestinal conditions and the integration of diagnostic testing into routine clinical practice further strengthen regional demand.
Asia Pacific (Fastest-Growing Region)
Asia Pacific is projected to experience the fastest growth, supported by a substantial burden of gastrointestinal infections, expanding diagnostic access, and improvements in healthcare infrastructure. Greater awareness of H. pylori-related health risks is encouraging more patients to seek diagnostic evaluation, while the expansion of hospitals, laboratories, and specialized testing facilities is improving availability. Rising healthcare expenditure and increasing adoption of modern diagnostic technologies are also helping broaden testing across both established and emerging healthcare markets in the region.
| Parameter | North America | Asia Pacific | Europe | Latin America | MEA |
|---|---|---|---|---|---|
| Innovation Hub i Scale Nascent Developing Advanced | |||||
| Cost-Sensitive Region i Scale Low Medium High | |||||
| Regulatory Environment i Scale Restrictive Neutral Supportive | |||||
| Demand Drivers i Scale Weak Moderate Strong | |||||
| Development Stage i Scale Emerging Developing Developed | |||||
| Adoption Rate i Scale Low Medium High | |||||
| New Entrants / Startups i Scale Sparse Moderate Dense | |||||
| Macro Indicators i Scale Weak Stable Strong |
Key Country Insights
Germany 🇩🇪
Evidence-Based Testing PracticesGermany emphasizes accurate Helicobacter pylori detection through validated laboratory and non-invasive diagnostic methods. German healthcare providers continue aligning testing practices with clinical guidelines to support effective gastrointestinal disease management.
France 🇫🇷
Diagnostic Guideline AlignmentFrance supports Helicobacter pylori diagnostics through standardized testing strategies and coordinated gastroenterology care. French healthcare providers emphasize reliable diagnosis and appropriate follow-up testing to improve treatment effectiveness and patient management.
Italy 🇮🇹
Clinical Testing EfficiencyItaly continues improving Helicobacter pylori diagnostics by expanding access to reliable laboratory and non-invasive testing methods. Italian healthcare providers focus on efficient diagnosis that supports evidence-based treatment decisions for gastrointestinal disorders.
Japan 🇯🇵
Gastric Disease DetectionJapan maintains strong clinical focus on Helicobacter pylori diagnostics due to continued emphasis on gastric disease prevention and management. Japanese healthcare institutions utilize reliable diagnostic methods alongside routine clinical evaluation for timely patient care.
South Korea 🇰🇷
Preventive Gastrointestinal CareSouth Korea is expanding access to accurate Helicobacter pylori diagnostic testing within preventive and clinical gastroenterology services. South Korean healthcare providers continue incorporating efficient laboratory and non-invasive diagnostic approaches into routine patient management.
United States 🇺🇸
Comprehensive Diagnostic PathwaysThe U.S. Helicobacter pylori diagnostics market combines non-invasive testing with endoscopic diagnostic approaches to improve gastrointestinal disease management. Healthcare providers across the U.S. increasingly integrate accurate diagnostic pathways with treatment monitoring and antimicrobial stewardship initiatives.
Segment Leadership and Growth Trends
Helicobacter Pylori Diagnostics Market Share (%), by Type, 2026
Go beyond the chart, access full insights & data tables
Request Free Sample ReportType Segment Analysis: Reagents (Largest Segment) vs Instruments (Fastest-Growing Segment)
Reagents dominated the type segment of the helicobacter pylori diagnostics market, accounting for a 47.14% share in 2026. Their leading position is supported by the routine requirement for diagnostic testing across clinical settings and the broad use of reagent-based approaches for detecting helicobacter pylori infection. The need for timely and reliable identification of infection, particularly in patients experiencing gastrointestinal symptoms, continues to sustain demand. Increasing awareness of infection-related gastric complications and greater emphasis on early diagnosis are also supporting consistent utilization of diagnostic reagents.
Instruments are expected to be the fastest-growing type as diagnostic providers increasingly seek efficient and dependable platforms for helicobacter pylori detection. Advancements in diagnostic technologies are supporting greater automation, workflow efficiency, and testing consistency, making instrument-based solutions increasingly relevant to modern laboratory environments. Growing demand for rapid diagnostic processes and the expansion of laboratory testing capabilities are further creating opportunities for instrument adoption.
End-user Segment Analysis: Hospitals (Largest Segment) vs Diagnostics Laboratories (Fastest-Growing Segment)
Hospitals held the largest share of the end-user segment of the helicobacter pylori diagnostics market, representing 47.32% in 2026. Hospitals remain important diagnostic settings because patients with gastrointestinal symptoms frequently undergo testing as part of broader clinical evaluation and treatment pathways. The availability of specialized healthcare professionals, laboratory infrastructure, and integrated diagnostic services enables hospitals to incorporate helicobacter pylori testing into routine patient management. Rising emphasis on identifying gastrointestinal infections and guiding appropriate treatment is reinforcing demand within hospital-based settings.
Diagnostics laboratories are projected to experience the fastest growth as testing increasingly shifts toward specialized and dedicated laboratory environments. These facilities can provide focused diagnostic capabilities, standardized testing workflows, and access to specialized analytical expertise, supporting efficient processing of helicobacter pylori tests. Increasing demand for accurate infection detection and the growing role of laboratory-based diagnostics in outpatient and clinical care are expected to strengthen the segment's expansion.
| Segment | Sub-Segment | Largest Segment | Fastest Growing |
|---|---|---|---|
| Type | Instruments, Reagents, Services | Reagents | Instruments |
| End-user | Hospitals, Diagnostics Laboratories, Clinics | Hospitals | Diagnostics Laboratories |
| Technology | Immunoassays, POC, Molecular Diagnostics | Immunoassays | Molecular Diagnostics |
Competitive Landscape and Market Positioning
Leading companies in the helicobacter pylori diagnostics market:
1. Thermo Fisher Scientific Inc. (United States)
2. Biohit Oyj (Finland)
3. Quest Diagnostics Incorporated (United States)
4. Meridian Bioscience Inc. (United States)
5. Bio-Rad Laboratories Inc. (United States)
6. Alpha Laboratories Ltd (United Kingdom)
7. F. Hoffmann-La Roche Ltd (Switzerland)
8. Coris BioConcept (Belgium)
9. Certest Biotec S.L. (Spain)
10. Epitope Diagnostics Inc. (United States)
Growing emphasis on early gastrointestinal disease detection is accelerating innovation within the helicobacter pylori diagnostics market. Market participants are introducing rapid diagnostic assays and non-invasive testing technologies designed to improve accuracy and patient convenience. Regulatory focus on reliable diagnostic performance is also encouraging the adoption of advanced molecular and immunological testing approaches across healthcare settings.
| Company | Market Share | Company Revenue | Revenue CAGR (%) | Product Portfolio | Geographic Presence | Innovation / R&D Focus | Strategic Developments |
|---|---|---|---|---|---|---|---|
| Thermo Fisher Scientific Inc. (United States) | |||||||
| Biohit Oyj (Finland) | |||||||
| Quest Diagnostics Incorporated (United States) | |||||||
| Meridian Bioscience Inc. (United States) | |||||||
| Bio-Rad Laboratories Inc. (United States) | |||||||
| Alpha Laboratories Ltd (United Kingdom) | |||||||
| F. Hoffmann-La Roche Ltd (Switzerland) | |||||||
| Coris BioConcept (Belgium) | |||||||
| Certest Biotec S.L. (Spain) | |||||||
| Epitope Diagnostics Inc. (United States). |
Industry Development/News
| Company Name | Date | Key Development |
|---|---|---|
| Quest Diagnostics Incorporated | Jan-25 | Quest Diagnostics expanded its outpatient gastrointestinal testing services across its integrated laboratory networks. This operational expansion increases diagnostic accessibility and throughput, allowing for broader clinical integration of H. pylori testing. The initiative aligns with a strategic focus on scaling gastrointestinal diagnostics to meet growing demand for routine screening and post-treatment monitoring in outpatient settings. |
| Meridian Bioscience, Inc. | Jan-24 | Meridian Bioscience launched rapid stool antigen testing kits specifically optimized for decentralized healthcare settings. This product release enhances the company's capability to deliver diagnostics outside of traditional centralized laboratory environments. The move reflects a strategic effort to improve patient access to testing while strengthening the firm’s competitive footprint in point-of-care gastrointestinal diagnostics. |
| F. Hoffmann-La Roche Ltd | Jan-24 | F. Hoffmann-La Roche advanced its AI-assisted molecular diagnostic technologies for gastrointestinal disease analysis. By integrating machine learning into diagnostic workflows, the company aims to improve accuracy and efficiency in pathogen detection. This development represents a significant technological integration, enhancing the firm's portfolio of sophisticated diagnostic tools used in the analysis and management of gastrointestinal infections. |
| Biomerica, Inc. | Dec-23 | Biomerica received FDA 510(k) clearance for its HP Detect Stool Antigen ELISA test. Designed for the detection and monitoring of H. pylori infection, the diagnostic tool provides medical providers with a standardized method to assess infection status. The commercialization of this test addresses a significant clinical need for reliable diagnostics in managing infections linked to chronic gastrointestinal conditions. |
| Meridian Bioscience, Inc. | Jul-23 | Meridian Bioscience received FDA clearance for its Premier HpSA FLEX, a non-invasive enzyme immunoassay for detecting H. pylori antigens. The product enhances diagnostic flexibility by accepting both fresh or frozen samples and those preserved in Cary-Blair and C&S media. This addition expands the company’s existing H. pylori diagnostic portfolio, strengthening its competitive position in non-invasive testing solutions. |
| Thermo Fisher Scientific | Jan-23 | Thermo Fisher Scientific expanded its molecular diagnostic capabilities specifically targeting gastrointestinal infection detection and antibiotic resistance profiling. The investment in advanced molecular tools strengthens the company’s position in the diagnostics market by providing higher-precision testing options. This expansion supports the broader adoption of molecular diagnostics for complex gastrointestinal health assessments and personalized treatment monitoring. |
| Bio-Rad Laboratories | Jan-23 | Bio-Rad Laboratories introduced enhanced immunoassay solutions designed to automate Helicobacter pylori screening workflows. By improving the efficiency of laboratory processing, this technological advancement supports high-volume diagnostic environments. The integration of automated screening capabilities helps medical facilities manage growing test volumes, contributing to improved operational efficiency and faster turnaround times in the clinical detection of H. pylori infections. |
Customize Your Report
Explore examples of how this report can be tailored to different research needs, including custom segments, additional topics or chapters, and related reports. Click a section of the wheel or its numbered marker to explore the available options.
Helicobacter Pylori Diagnostics Market — Custom Segments
| Segment | Sub-Segment |
|---|---|
| Sample Type | Blood, Stool, Urea Breath, Gastric Tissue |
| Testing Purpose | Initial Diagnosis, Confirmation of Eradication, Recurrence Detection |
| Care Pathway Stage | Screening & Initial Assessment, Diagnostic Confirmation, Post-Treatment Monitoring |
Helicobacter Pylori Diagnostics Market — Custom
| Custom Chapter | Custom Details |
|---|---|
| Gastroenterology Testing Pathway Assessment |
|
| Non-Invasive Diagnostics Adoption |
|
| Antimicrobial Resistance Impact on Diagnostic Demand |
|
Need a different cut of the data?
Request Custom ResearchWhat is the current revenue of the helicobacter pylori diagnostics market?
How is the helicobacter pylori diagnostics industry size expected to evolve during the forecast period?
How is the shift toward non-invasive testing influencing adoption in the helicobacter pylori diagnostics market?
Why are molecular diagnostic technologies becoming strategically important in the helicobacter pylori diagnostics market?
Why are Reagents the leading segment in the helicobacter pylori diagnostics market?
Why are Diagnostics Laboratories the fastest-growing end-user segment?
Why does North America lead the helicobacter pylori diagnostics market?
What is driving growth in Asia Pacific for helicobacter pylori diagnostics?
Which companies are driving growth in the helicobacter pylori diagnostics landscape?
Our Clients
"The reports offered a comprehensive view of the Food and Beverage landscape, covering market trends, consumer behavior, and competitive dynamics."
"Our experience in acquiring market research reports has been outstanding — the depth of analysis and actionable insights have proven invaluable."
"Fundamental Business Insights demonstrated a keen understanding of our business needs, delivering reports tailored to our specific objectives."
Our Research Team & Methodology
Every Fundamental Business Insights report is built by a dedicated vertical research team, validated through a structured primary-and-secondary methodology, and reviewed for accuracy before it reaches you.
Research Team Overview
Prepared by the Healthcare & Medical Devices Research Team
Delivery
Published
Demand
Available
Support
Trust & Compliance
Research Domains
10 coverage areasResearch Intelligence
| Source | Why It Matters | Reference |
|---|---|---|
| World Health Organization (WHO) | Global health statistics, disease burden, healthcare policies | www.who.int |
| U.S. Food & Drug Administration (FDA) | Medical devices, pharmaceuticals, diagnostics, approvals | www.fda.gov |
| European Medicines Agency (EMA) | Pharmaceutical approvals and regulatory guidance in Europe | www.ema.europa.eu |
| Centers for Disease Control and Prevention (CDC) | Disease surveillance, public health, epidemiology | www.cdc.gov |
| National Institutes of Health (NIH) | Biomedical research, clinical studies, funding | www.nih.gov |
| National Center for Biotechnology Information (NCBI) | Biomedical databases, PubMed, genomics | www.ncbi.nlm.nih.gov |
| PubMed | Peer-reviewed biomedical literature | pubmed.ncbi.nlm.nih.gov |
| ClinicalTrials.gov | Global clinical trial registry | clinicaltrials.gov |
| International Organization for Standardization (ISO) | Medical device quality and healthcare standards | www.iso.org |
| ASTM International | Medical device testing and material standards | www.astm.org |
| Advanced Medical Technology Association (AdvaMed) | Medical devices and diagnostics industry | www.advamed.org |
| Medical Device Innovation Consortium (MDIC) | Medical device innovation and regulatory science | mdic.org |
| Biotechnology Innovation Organization (BIO) | Biotechnology industry developments | www.bio.org |
| International Federation of Pharmaceutical Manufacturers & Associations (IFPMA) | Global pharmaceutical industry | www.ifpma.org |
| U.S. Pharmacopeia (USP) | Drug quality standards and reference materials | www.usp.org |
| European Directorate for the Quality of Medicines & HealthCare (EDQM) | European pharmaceutical quality standards | www.edqm.eu |
| World Organisation for Animal Health (WOAH) | Veterinary healthcare and animal diseases | www.woah.org |
| American Hospital Association (AHA) | Hospital operations and healthcare delivery | www.aha.org |
| OECD Health | International healthcare expenditure and system statistics | www.oecd.org/health |
| World Bank Data | Healthcare expenditure and demographic indicators | data.worldbank.org |
Research Workflow & Quality Assurance
Data Collection
Verified information gathered through primary and secondary research.
Data Triangulation
Cross-validation using multiple independent data sources.
Forecast Modelling
Market estimates developed using historical trends and analytical models.
Analyst Validation
Findings reviewed by domain experts for accuracy and consistency.
Editorial & Quality Review
Final editorial, quality, and compliance checks before publication.
Final Publication
Released after successful completion of the internal review process.
Report Coverage
📊 Market Assessment
- Market Size & Forecast
- Market Segmentation
- Regional Analysis
- Growth Drivers & Challenges
- Market Dynamics
🏢 Competitive Intelligence
- Competitive Landscape
- Company Profiles
- Competitive Benchmarking
- Mergers & Acquisitions
- Market Share Analysis or Key Company Strategies
🔍 Strategic Analysis
- Value Chain Analysis
- Porter's Five Forces
- PESTLE Analysis
- Pricing Trends
- Supply-Demand Analysis
🚀 Future Outlook
- Technology Landscape
- Regulatory Landscape
- Investment & Funding Landscape
- Emerging Opportunities
- Future Market Outlook
Have a question about this report or need a custom scope?
Request Customization